Stephens analyst Sudan Loganathan raised the firm’s price target on Pyxis Oncology (PYXS) to $8 from $5 and keeps an Overweight rating on the shares, citing “growing conviction” around MICVO and its potential to be a competitive treatment option for recurrent or metastatic head and neck squamous cell carcinoma.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PYXS:
- Pyxis Oncology Reports Increased Losses Amid Development Focus
- Promising Efficacy of Pyxis Oncology’s MICVO in HNSCC Justifies Buy Rating Despite Financial Constraints
- Buy Rating for Pyxis Oncology: Promising Clinical Data and Strong Financial Position
- Promising Developments in Pyxis Oncology’s MICVO Drive Buy Rating
- Pyxis Oncology reports Q3 EPS (35c), consensus (34c)